Hypertension, Vol 5, 837-843, Copyright © 1983 by American Heart Association
L Corea, M Bentivoglio and P Verdecchia
We tried to assess relationships between echocardiographic left ventricular
hypertrophy (LVH), arterial pressure levels, and plasma norepinephrine
concentration (NE) in 20 previously untreated stable hypertensive patients
with LVH, and in 11 healthy normotensive control subjects. Interventricular
septal (IVS) thickness, posterior wall (PW) thickness, and left ventricular
mass index (LVMI) were related to arterial pressure levels and to NE by
univariate and multivariate regression analyses. In addition, after 18
months of monotherapy with atenolol (carried out in nine of 20 patients),
the relationship between echocardiographic changes and degree of pressure
reduction was tested. Before treatment, PW thickness weakly correlated with
systolic (r = 0.55; p less than 0.01) and mean (r = 0.50; p less than 0.05)
arterial pressure. IVS thickness weakly correlated with NE (r = 0.53; p
less than 0.05). On this relatively small sample, multivariate regression
analysis showed an association of both IVS thickness (R = 0.57; p less than
0.05) and PW thickness (R = 0.58; p less than 0.05) with mean arterial
pressure (MAP) and NE. After atenolol, there was a reduction in IVS
thickness (1.15 to 1.02 cm; p less than 0.01), PW thickness (1.08 to 0.99
cm; p less than 0.01), and LVMI (136.3 to 113.8 g/m2; p less than 0.01),
besides a significant reduction in blood pressure and heart rate. The
degree of pressure reduction induced by treatment did not correlate the
change in IVS or PW thickness. In contrast, the change in diastolic and
mean arterial pressure positively correlated the change in LVMI (r = 0.72
and r = 0.75, respectively; both p less than 0.05).(ABSTRACT TRUNCATED AT
250 WORDS)
ARTICLES
Echocardiographic left ventricular hypertrophy as related to arterial pressure and plasma norepinephrine concentration in arterial hypertension. Reversal by atenolol treatment
This article has been cited by other articles:
![]() |
P. Verdecchia, P. Sleight, G. Mancia, R. Fagard, B. Trimarco, R. E. Schmieder, J.-H. Kim, G. Jennings, P. Jansky, J.-H. Chen, et al. Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease Circulation, October 6, 2009; 120(14): 1380 - 1389. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1983 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |